Mounting Regulatory and Legal Challenges Pressure Hims & Hers Stock
Published on 02/17/2026 at 13:21 | Redaktion boerse-global.de
The telehealth company Hims & Hers finds itself navigating a perfect storm of regulatory scrutiny and legal action, leading to significant pressure on its share price. The stock has lost more than half its value since the start of the year as several critical issues converge.
A primary source of tension stems from the company’s brief foray into offering unapproved, compounded weight-loss medications. According to a Reuters report, the U.S. Food and Drug Administration (FDA) has referred Hims & Hers to the Department of Justice (DoJ). This action followed the FDA’s stated intention to take decisive steps to restrict GLP-1 ingredients in compounded drugs that lack its Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
